Abvc Biopharma Inc (ABVC) Stock Price, Quote & News

Company Profile

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple-negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 668 0881

Website: www.abvcpharma.com

Address:

44370 Old Warm Springs Boulevard, Fremont, United States

specctham Jun. 18 at 7:01 PM

$ABVC Pullback before explosion ?

0 · Reply

Ramiak Jun. 17 at 4:48 PM

$ABVC when the dividend is confirmed then it will explode. Looking the overall PR-s then this company likes to give more good news then any other company what’s in my portfolio. Quite sure the dividend news will come.

1 · Reply

specctham Jun. 17 at 3:35 PM

$ABVC It just never explodes. Like only many + days in a row. It looks like 1.6s from here

0 · Reply

BigdollarMaker Jun. 17 at 1:38 PM

$ABVC Oh yeah

0 · Reply

jacksparo Jun. 16 at 10:10 PM

$ABVC Here it is!

0 · Reply

jacksparo Jun. 16 at 10:09 PM

$ABVC In the right path since my first alert about it few weeks ago! I did alert this in my premium Telegram group!

0 · Reply

Ca1iman Jun. 16 at 8:08 PM

$ABVC sold this held bag for high of day and out. Good riddance.

1 · Reply

specctham Jun. 16 at 8:07 PM

$ABVC

0 · Reply

ProfitGainer Jun. 16 at 6:18 PM

$ABVC More good news that brokers like $BULL or $ETFC aren't reporting to us. https://www.nasdaq.com/press-release/aibtl-biopharma-strengthens-partnership-abvc-biopharma-paying-150000-licensing-fees

1 · Reply

BigdollarMaker Jun. 16 at 6:00 PM

$ABVC $ACB $BB

0 · Reply

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

Oct 22, 2024, 8:45 AM EDT - 8 months ago

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Aug 15, 2024, 7:30 AM EDT - 11 months ago

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Apr 18, 2024, 9:25 AM EDT - 1 year ago

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Apr 17, 2024, 9:00 AM EDT - 1 year ago

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Apr 10, 2024, 8:30 AM EDT - 1 year ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Mar 26, 2024, 8:30 AM EDT - 1 year ago

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Mar 19, 2024, 8:30 AM EDT - 1 year ago

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Mar 14, 2024, 9:30 AM EDT - 1 year ago

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Feb 15, 2024, 8:30 AM EST - 1 year ago

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Feb 12, 2024, 8:30 AM EST - 1 year ago

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Feb 8, 2024, 9:17 AM EST - 1 year ago

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Jan 3, 2024, 7:24 AM EST - 1 year ago

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Dec 7, 2023, 8:30 AM EST - 1 year ago

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Nov 21, 2023, 8:30 AM EST - 1 year ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Nov 16, 2023, 10:05 AM EST - 1 year ago

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Nov 15, 2023, 9:00 AM EST - 1 year ago

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Oct 26, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Oct 17, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Oct 9, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

Aug 23, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

Aug 17, 2023, 9:19 AM EDT - 2 years ago

ABVC Executes Cooperation Agreement for Strategic Investments

Aug 10, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

ABVC Corporate Update and CEO's Letter to Shareholders

Aug 3, 2023, 9:20 AM EDT - 2 years ago

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

Aug 1, 2023, 8:30 AM EDT - 2 years ago

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

Jul 31, 2023, 9:30 AM EDT - 2 years ago

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

Jul 27, 2023, 9:22 AM EDT - 2 years ago

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

Jul 26, 2023, 8:30 AM EDT - 2 years ago

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

Jul 24, 2023, 12:30 PM EDT - 2 years ago

ABVC BioPharma Announces Reverse Stock Split

Jul 6, 2023, 8:30 AM EDT - 2 years ago

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

Jun 26, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

Jun 20, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

Jun 12, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Jun 6, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

May 22, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

Apr 10, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Apr 6, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Mar 31, 2023, 6:49 PM EDT - 2 years ago

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Mar 20, 2023, 7:00 AM EDT - 2 years ago

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

Mar 14, 2023, 7:00 AM EDT - 2 years ago

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

Feb 28, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Provides 2023 Pipeline Update

Feb 23, 2023, 4:16 PM EST - 2 years ago

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Feb 21, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

Jan 19, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Jan 5, 2023, 8:30 AM EST - 2 years ago

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

Nov 17, 2022, 8:30 AM EST - 2 years ago

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

Nov 14, 2022, 6:20 PM EST - 2 years ago

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

Nov 7, 2022, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Nov 2, 2022, 8:30 AM EDT - 2 years ago

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

specctham Jun. 18 at 7:01 PM

$ABVC Pullback before explosion ?

0 · Reply

Ramiak Jun. 17 at 4:48 PM

1 · Reply

specctham Jun. 17 at 3:35 PM

$ABVC It just never explodes. Like only many + days in a row. It looks like 1.6s from here

0 · Reply

BigdollarMaker Jun. 17 at 1:38 PM

$ABVC Oh yeah

0 · Reply

jacksparo Jun. 16 at 10:10 PM

$ABVC Here it is!

0 · Reply

jacksparo Jun. 16 at 10:09 PM

$ABVC In the right path since my first alert about it few weeks ago! I did alert this in my premium Telegram group!

0 · Reply

Ca1iman Jun. 16 at 8:08 PM

$ABVC sold this held bag for high of day and out. Good riddance.

1 · Reply

specctham Jun. 16 at 8:07 PM

$ABVC

0 · Reply

ProfitGainer Jun. 16 at 6:18 PM

$ABVC More good news that brokers like $BULL or $ETFC aren't reporting to us. https://www.nasdaq.com/press-release/aibtl-biopharma-strengthens-partnership-abvc-biopharma-paying-150000-licensing-fees

1 · Reply

BigdollarMaker Jun. 16 at 6:00 PM

$ABVC $ACB $BB

0 · Reply

specctham Jun. 14 at 10:56 AM

$ABVC Anyone have past experience with this dividend policy ABVC are planning? share-based dividend in its subsidiary company. WHAT IF; The sec approved this, and AiBtl goes public on Nasdaq. Will we be allowed to sell these x shares on IPO day and take the cash. Or will there be lock-up period before dividend shares can be traded? If AiBtl shares will be traded $5-10 at IPO, thats a lot if one has many shares…

1 · Reply

ProfitGainer Jun. 12 at 6:41 PM

$ABVC Just broke the 52 week high.

0 · Reply

BigdollarMaker Jun. 12 at 5:40 PM

$ABVC Is getting hot $$$

0 · Reply

ProfitGainer Jun. 12 at 5:02 PM

$ABVC When dividends are confirmed, it will for sure blast off. https://www.nasdaq.com/press-release/abvc-biopharma-announces-board-approval-share-dividend-showing-confidence-subsidiary

1 · Reply

specctham Jun. 11 at 6:03 PM

$ABVC Teasing slowly at new ATHs per y. Just explode to 4 pls, so I can buy nintendo switch 2.

0 · Reply

BigdollarMaker Jun. 11 at 2:01 PM

$ABVC Drop before the pop$$$

0 · Reply

ProfitGainer Jun. 10 at 8:53 PM

$ABVC Not bad for a Tuesday. The higher it gets before news the better.

1 · Reply

BigdollarMaker Jun. 10 at 1:53 PM

$ABVC Holding strong

0 · Reply

specctham Jun. 5 at 8:31 PM

$ABVC Nice ending, shit man. what will happen tomorrow and next week may be exciting.

0 · Reply

BigdollarMaker Jun. 5 at 7:47 PM

$ABVC

0 · Reply

specctham Jun. 4 at 3:19 PM

$ABVC Lost momrntum, fuck

0 · Reply

PharmaExpert Jun. 3 at 3:53 PM

$AKBA, $RSLS, $AGEN, $ABVC, $ESPR! 🔥🔥🔥🔥🔥

1 · Reply

Market Cap	31.25M
Revenue (ttm)	510,000.00
Net Income (ttm)	-4.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-960.78%
Debt to Equity Ratio	0.00

Volume	199,300
Avg Vol	296,394
Day's Range	N/A - N/A
Shares Out	16.98M
Stochastic %K	41%
Beta	0.19
Analysts	Strong Buy
Price Target	$20.20